Eli Lilly and BAI collaborate on Phase 3 prevention trial of anti-beta amyloid antibody donanemab

Eli Lilly and the Banner Alzheimer's Institute (BAI) recently announced a strategic research collaboration to carry out a phase 3 preventive trial of the anti-beta amyloid antibody donanemab (TRAILBLAZER-ALZ 3 )

Eric M.

Beta amyloid plaques exist in the brains of AD patients (Image source: hysiciansweekly.

TRAILBLAZER-ALZ is a randomized, placebo-controlled, double-blind, multicenter Phase 2 study to evaluate the safety, tolerability and efficacy of donanemab in the treatment of early symptomatic AD

The results announced in January this year showed that the study reached the primary endpoint: the change in iADRS score from baseline to week 76, compared with the placebo group, delayed the decline by 32% in the donanemab group

By targeting N3pGβ amyloid, donanemab treatment has been shown to rapidly lead to high-level clearance of amyloid plaques, as measured by amyloid imaging

In this study, the safety of donanemab is consistent with the observations of the phase I study data.

Original source: Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab